Top

Published in:

Open Access 01-09-2010 | Case Report

Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii

Authors: Wei Ji, Juan Li, Yue Lin, Ya-nan Song, Miaojia Zhang, Yao Ke, Yile Ren, Xiaohu Deng, Jianglin Zhang, Feng Huang, David Yu

Published in: Clinical Rheumatology | Issue 9/2010

Abstract

Objective

Description of the clinical response of 12 consecutive cases of disease-active ankylosing spondylitis (AS) treated with the herbal medicine Tripterygium wilfordii Hook f (TwHf; lei gong teng, thunder god vine), which has been reported in controlled studies to be effective in rheumatoid arthritis (RA).

Methods

The clinical status of 12 patients with active AS who were started on 60 mgday^-1 of a commercial tablet preparation of TwHf extract. were monitored at weeks 1, 3, and 6.

Results

Compared to baseline, there was significant improvement in mean values of physician assessment, Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), and Bath ankylosing spondylitis global score (BAS-G) at weeks 3 and 6, with no changes in liver enzymes or complete blood count (CBC).

Conclusion

A placebo-controlled double-blind study for Tripterygium is warranted. Until then, this particular report should be considered as case reports and not an endorsement of the use of Tripterygium in clinical practice.

Brinier AM, Ma J, Lipsky PE, Raskin I (2007) Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68(6):732–766CrossRef

Lipsky PE, Tao XL (1997) A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 26(5):713–723CrossRefPubMed

Zhang X, Chi Z (2004) Lei gong teng zai feng shi xing ji bing zhong de ying yong gai shu. Henan Tad Chin Med 24(3):80–82

Canter PH, Lee HS, Ernst E (2006) A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis. Phytomedicine 13(5):371–377CrossRefPubMed

Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P et al (2009) Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 151(4):229–240PubMed

Tao X, Younger J, Fan FZ, Wang B, Lipsky PE (2002) Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 46(7):1735–1743CrossRefPubMed

Tao XL, Dong Y, Zhang NZ (1987) A double-blind study of T2 (tablets of polyglycosides of Tripterygium wilfordii Hook) in the treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 26:399–402PubMed

Guo J, Yuan S, Wang X, Xu S, Li D (1981) Tripterygium wilfordii Hook f in rheumatoid arthritis and ankylosing spondylitis. Preliminary report. Chin Med J 94(7):405–412PubMed

Sieper J, Rudwaleit M, Khan MA, Braun J (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20(3):401–417CrossRefPubMed

10.

Zochling J (2008) Assessment and treatment of ankylosing spondylitis: current status and future directions. Curr Opin Rheumatol 20(4):398–403CrossRefPubMed

11.

van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed

12.

Pang L, Wang L, Suo T, Hao H, Fang X, Jia J et al (2008) Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis. J Rheumatol 35(11):2220–2228CrossRefPubMed

13.

Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21(12):2281–2285PubMed

14.

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21(12):2286–2291PubMed

15.

Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath as metrology index. J Rheumatol 21(9):1694–1698PubMed

16.

Jones SD, Steiner A, Garrett SL, Calin A (1996) The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35(1):66–71CrossRefPubMed

17.

Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886CrossRefPubMed

18.

Wan T (2005) The adverse reaction of lei gong teng. Pract Clin Med 6:149–150

19.

Inman RD, Davis JC Jr, Heijde DV, Diekman L, Sieper J, Kim SI et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412CrossRefPubMed

20.

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591CrossRefPubMed

21.

van der Heijde D, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H, et al (2008) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis

22.

Tang Y, Zhang X, Su B (1998) The adverse reaction of lei gong teng application in dermatology. J Clin Dermatol 27:377

Title: Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii
Authors: Wei Ji
Juan Li
Yue Lin
Ya-nan Song
Miaojia Zhang
Yao Ke
Yile Ren
Xiaohu Deng
Jianglin Zhang
Feng Huang
David Yu
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 9/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1497-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2010

Fungal arthritis of the knee caused by Mycoleptodiscus indicus

Anti-Ro antibody and clinical manifestations: lessons from systemic lupus erythematosus in the elderly

Validation of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-31) in Chinese

Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis

Low-level laser therapy for hand arthritis—fact or fiction?

Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials